Predictors of response to low-dose amitriptyline for irritable bowel syndrome and efficacy and tolerability according to subtype: post hoc analyses from the ATLANTIS trial
Predictors of response to low-dose amitriptyline for irritable bowel syndrome and efficacy and tolerability according to subtype: post hoc analyses from the ATLANTIS trial
Background: low-dose amitriptyline, a tricyclic antidepressant (TCA), was superior to placebo for irritable bowel syndrome (IBS) in the AmitripTyline at Low-dose ANd Titrated for Irritable bowel syndrome as Second-line treatment (ATLANTIS) trial.
Objective: to perform post hoc analyses of ATLANTIS for predictors of response to, and tolerability of, a TCA.
Design: ATLANTIS randomised 463 adults with IBS to amitriptyline (232) or placebo (231). We examined the effect of baseline demographic and disease-related patient characteristics on response to amitriptyline and the effect of amitriptyline on individual symptoms and side effects by subtype.
Results: there was a quantitative difference in amitriptyline effectiveness in those ≥50 years vs <50 on the IBS severity scoring system (IBS-SSS) (interaction p=0.048, mean difference in ≥50 years subgroup −46.5; 95% CI −74.2 to −18.8, p=0.0010), and subjective global assessment of relief (interaction p=0.068, OR in ≥50 years subgroup 2.59; 95% CI 1.47 to 4.55, p=0.0010), and those in the 70% most deprived areas of England compared with the 30% least deprived for a ≥30% improvement in abdominal pain (interaction p=0.021, OR in 70% most deprived subgroup 2.70; 95% CI 1.52 to 4.77, p=0.0007). Stronger treatment effects were seen in men, with higher Patient Health Questionnaire-12 scores, and with IBS with diarrhoea. Mean differences in individual IBS-SSS components favoured amitriptyline, and side effects were similar, across almost all IBS subtypes.
Conclusion: these exploratory analyses demonstrate there are unlikely to be deleterious effects of amitriptyline in any particular IBS subtype and could help identify patients in whom amitriptyline may be more effective.
ABDOMINAL PAIN, IRRITABLE BOWEL SYNDROME
728-739
Wright-Hughes, Alexandra
d329a17b-afa9-45a4-88b8-563863b71559
Ow, Pei-Loo
2aa6c631-e297-4d11-80f3-46f88134202c
Alderson, Sarah L.
354474d1-a5f6-434f-a3cb-3d85de1e34af
Ridd, Matthew J.
649cb818-ed8f-4c44-8ad1-ee5eda989497
Foy, Robbie
b1c850e8-d910-4b96-b09e-d241761ad2ae
Bishop, Flis
1f5429c5-325f-4ac4-aae3-6ba85d079928
Chaddock, Matthew
f2c1c2fd-bc9a-462d-8aad-7bb2eab7e36e
Fernandez, Catherine
9fde365c-97a4-4a96-99f0-dd164572cfe0
Guthrie, Elspeth A.
62a7c6c1-22d1-47be-9425-5dee7199ee2e
Muir, Delia P.
1f7b2eba-0129-4eda-bf49-40266b80bb4f
Taylor, Christopher A.
35381698-d43c-4fc4-8774-1ff5432dbd4e
Farrin, Amanda J.
0327d9c2-55d5-4136-9800-d73bb56f50b4
Everitt, Hazel
80b9452f-9632-45a8-b017-ceeeee6971ef
Ford, Alexander C.
fa466212-d97b-4468-801b-d5f2b4fe7538
7 April 2025
Wright-Hughes, Alexandra
d329a17b-afa9-45a4-88b8-563863b71559
Ow, Pei-Loo
2aa6c631-e297-4d11-80f3-46f88134202c
Alderson, Sarah L.
354474d1-a5f6-434f-a3cb-3d85de1e34af
Ridd, Matthew J.
649cb818-ed8f-4c44-8ad1-ee5eda989497
Foy, Robbie
b1c850e8-d910-4b96-b09e-d241761ad2ae
Bishop, Flis
1f5429c5-325f-4ac4-aae3-6ba85d079928
Chaddock, Matthew
f2c1c2fd-bc9a-462d-8aad-7bb2eab7e36e
Fernandez, Catherine
9fde365c-97a4-4a96-99f0-dd164572cfe0
Guthrie, Elspeth A.
62a7c6c1-22d1-47be-9425-5dee7199ee2e
Muir, Delia P.
1f7b2eba-0129-4eda-bf49-40266b80bb4f
Taylor, Christopher A.
35381698-d43c-4fc4-8774-1ff5432dbd4e
Farrin, Amanda J.
0327d9c2-55d5-4136-9800-d73bb56f50b4
Everitt, Hazel
80b9452f-9632-45a8-b017-ceeeee6971ef
Ford, Alexander C.
fa466212-d97b-4468-801b-d5f2b4fe7538
Wright-Hughes, Alexandra, Ow, Pei-Loo, Alderson, Sarah L., Ridd, Matthew J., Foy, Robbie, Bishop, Flis, Chaddock, Matthew, Fernandez, Catherine, Guthrie, Elspeth A., Muir, Delia P., Taylor, Christopher A., Farrin, Amanda J., Everitt, Hazel and Ford, Alexander C.
(2025)
Predictors of response to low-dose amitriptyline for irritable bowel syndrome and efficacy and tolerability according to subtype: post hoc analyses from the ATLANTIS trial.
Gut, 74 (5), , [gutjnl-2024-334490].
(doi:10.1136/gutjnl-2024-334490).
Abstract
Background: low-dose amitriptyline, a tricyclic antidepressant (TCA), was superior to placebo for irritable bowel syndrome (IBS) in the AmitripTyline at Low-dose ANd Titrated for Irritable bowel syndrome as Second-line treatment (ATLANTIS) trial.
Objective: to perform post hoc analyses of ATLANTIS for predictors of response to, and tolerability of, a TCA.
Design: ATLANTIS randomised 463 adults with IBS to amitriptyline (232) or placebo (231). We examined the effect of baseline demographic and disease-related patient characteristics on response to amitriptyline and the effect of amitriptyline on individual symptoms and side effects by subtype.
Results: there was a quantitative difference in amitriptyline effectiveness in those ≥50 years vs <50 on the IBS severity scoring system (IBS-SSS) (interaction p=0.048, mean difference in ≥50 years subgroup −46.5; 95% CI −74.2 to −18.8, p=0.0010), and subjective global assessment of relief (interaction p=0.068, OR in ≥50 years subgroup 2.59; 95% CI 1.47 to 4.55, p=0.0010), and those in the 70% most deprived areas of England compared with the 30% least deprived for a ≥30% improvement in abdominal pain (interaction p=0.021, OR in 70% most deprived subgroup 2.70; 95% CI 1.52 to 4.77, p=0.0007). Stronger treatment effects were seen in men, with higher Patient Health Questionnaire-12 scores, and with IBS with diarrhoea. Mean differences in individual IBS-SSS components favoured amitriptyline, and side effects were similar, across almost all IBS subtypes.
Conclusion: these exploratory analyses demonstrate there are unlikely to be deleterious effects of amitriptyline in any particular IBS subtype and could help identify patients in whom amitriptyline may be more effective.
Text
gutjnl-2024-334490R1_CLEAN
- Accepted Manuscript
More information
e-pub ahead of print date: 8 January 2025
Published date: 7 April 2025
Keywords:
ABDOMINAL PAIN, IRRITABLE BOWEL SYNDROME
Identifiers
Local EPrints ID: 499542
URI: http://eprints.soton.ac.uk/id/eprint/499542
ISSN: 1468-3288
PURE UUID: fd96af48-bb04-4054-b7ce-9bff85c82b65
Catalogue record
Date deposited: 25 Mar 2025 18:04
Last modified: 03 Sep 2025 01:38
Export record
Altmetrics
Contributors
Author:
Alexandra Wright-Hughes
Author:
Pei-Loo Ow
Author:
Sarah L. Alderson
Author:
Matthew J. Ridd
Author:
Robbie Foy
Author:
Matthew Chaddock
Author:
Catherine Fernandez
Author:
Elspeth A. Guthrie
Author:
Delia P. Muir
Author:
Christopher A. Taylor
Author:
Amanda J. Farrin
Author:
Alexander C. Ford
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics